Analysts See $-0.22 EPS for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on March, 11

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Corporate Logo

Investors expect Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)’s quarterly earnings on March, 11., as reported by Faxor. Analysts expect change of 10.00 % or $0.02 from previous year’s $-0.2 EPS compared to current’s $-0.22 EPS. Wall Street now sees -15.38 % EPS growth despite Corbus Pharmaceuticals Holdings, Inc. last quarter’s EPS of $-0.26. The stock decreased 0.52% or $0.04 during the last trading session, touching $7.64.Corbus Pharmaceuticals Holdings, Inc. has volume of 522,346 shares. Since February 12, 2018 CRBP has declined 9.87% and is downtrending. CRBP underperformed the S&P500 by 9.87%.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Ratings Coverage

In total 4 analysts cover Corbus Pharmaceuticals (NASDAQ:CRBP). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 4 are the (NASDAQ:CRBP)’s analyst reports since September 14, 2018 according to StockzIntelligence Inc. In Friday, September 14 report Cantor Fitzgerald maintained the stock with “Overweight” rating.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases.The company has $478.55 million market cap. The Company’s lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases.Last it reported negative earnings.

For more Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) news published briefly go to: Globenewswire.com, Fool.com, Seekingalpha.com, Finance.Yahoo.com or Globenewswire.com. The titles are as follows: “Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies – GlobeNewswire” published on October 22, 2018, “Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals – The Motley Fool” on November 24, 2018, “Corbus And Inventiva In Systemic Sclerosis: Looking Good – Seeking Alpha” with a publish date: January 07, 2019, “5 Marijuana Stocks to Stay Far Away From – Yahoo Finance” and the last “Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock – GlobeNewswire” with publication date: January 25, 2019.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.